Bloodbuy Announces Agreement With Cerus Corporation To Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex On Its Digital Marketplace
Portfolio Pulse from Benzinga Newsdesk
Healthcare software and services company Bloodbuy has entered into an agreement with Cerus Corporation (NASDAQ:CERS) to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (IFC) via the Bloodbuy online marketplace. The IFC is a pathogen reduced blood component for fibrinogen supplementation with a 5-day post-thaw shelf life. This new blood product has the potential to make a huge impact on patient outcomes.
November 01, 2023 | 6:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cerus Corporation has entered into an agreement with Bloodbuy to offer its Pathogen Reduced Cryoprecipitated Fibrinogen Complex on the Bloodbuy online marketplace. This could potentially increase the reach and sales of the product.
The partnership with Bloodbuy could potentially increase the reach and sales of Cerus Corporation's Pathogen Reduced Cryoprecipitated Fibrinogen Complex. This could have a positive impact on the company's revenues and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100